XM does not provide services to residents of the United States of America.

Daily Market Comment – Bonds and dollar steady, stocks mixed ahead of Fed



  • Fed decision awaited as 10-year Treasury yields hold above 1.60%
  • Dollar flat, Wall Street futures slip as investors brace for Fed inaction
  • EU’s vaccine shambles continue, euro battles to defend $1.19 level

More jawboning expected as Fed to stay course

Markets were in a calm mood on Wednesday, though sentiment erred on the side of caution as uncertainty around the FOMC decision kept investors on edge. The Federal Reserve is highly anticipated to hold rates and its stimulus programmes unchanged when it announces its latest policy decision at 18:00 GMT. However, as speculation mounts about how soon policymakers will begin to raise rates now that the US recovery has been cemented with a massive cash boost from Congress and an accelerating vaccination campaign, the updated dot plot chart will take centre stage.

The Fed had planned to freeze its key policy rate near zero through the end of 2023 in December. But the fast-improving outlook for the US economy could push the central bank’s median projection upwards if more FOMC members pencil in a rate hike in 2023 at the March meeting than back in December. Such a move is all it would take to spark fresh panic in bond and stock markets, boosting yields and pummelling shares on Wall Street.

So the question is, will Chair Powell try to contain the surge in yields by providing an explicit warning on what action the Fed could take to counter the move in bond markets, or will he stick to the familiar jawboning of playing down the optimism and simply reiterating the forward guidance?

If it’s the latter, it’s almost certain the yield on 10-year Treasury notes will soon fly past last week’s fresh 13-month peak of 1.642%, bruising risk assets in the process.

Stocks subdued ahead of Fed, upbeat outlook lends support

For now, with the exception of the tech sector, US equities are still riding this wave of optimism, setting all-time highs only this week, as there’s little that can dent the positive outlook, especially for the old economy stocks that stand to benefit the most from the eventual lifting of most virus restrictions.

US stock futures were drifting lower today, having pulled away from yesterday’s intra-day records. This weighed on Asian and European shares, which were mixed today, as investors anxiously awaited the outcome of the Fed meeting.

Europe’s ongoing vaccine woes are so far having a limited dampening effect on the region’s stock markets, with Germany’s export-heavy DAX 30 index trading near record territory today, but they have been a bit of a drag on the euro lately. Several EU nations have temporarily banned AstraZeneca’s jab after reports of some patients developing blood clots, dealing a major blow to the bloc’s already hampered efforts to get up to speed with its shambolic vaccine rollout. The European Medical Agency will announce its findings tomorrow on whether the AstraZeneca vaccine increases the risk of blood clots.

Euro and pound test key levels as dollar holds firm

The euro hovered around the $1.19 level as it struggled to halt a three-day decline following its failure last week to stretch its rebound past the $1.20 mark. The pound also seems to be unable to restore its positive footing against the US dollar and has been consolidating for almost a month now amid the jump in Treasury yields. But there could be some good news for the British currency tomorrow if the Bank of England sounds a more upbeat tone at its latest policy meeting.

The greenback was flat against a basket of currencies, but it was slightly firmer versus the yen at 109.10.

The Australian dollar was today’s worst performer, slipping about 0.20% against its US counterpart, while the kiwi and loonie fell too.

Gold prices continued to crawl higher despite bond yields staying elevated as investors sought a hedge against the risk of higher inflation amid the rise in future price expectations. The precious metal was last up 0.30% at $1736/oz.

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.